Toronto Dominion Bank Lowers Holdings in Catalent, Inc. (NYSE:CTLT)

Toronto Dominion Bank reduced its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 76.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,932 shares of the company's stock after selling 298,815 shares during the quarter. Toronto Dominion Bank's holdings in Catalent were worth $5,447,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Athos Capital Ltd bought a new stake in shares of Catalent during the third quarter worth $6,009,000. State Street Corp increased its stake in Catalent by 1.5% in the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company's stock worth $451,315,000 after buying an additional 113,095 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in Catalent during the 3rd quarter valued at about $1,131,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock valued at $24,550,000 after buying an additional 14,373 shares during the period. Finally, Quest Partners LLC grew its stake in Catalent by 289.8% in the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company's stock worth $2,986,000 after acquiring an additional 36,652 shares in the last quarter.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company's stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last 90 days. Insiders own 0.31% of the company's stock.

Catalent Stock Up 0.0 %

Shares of NYSE CTLT traded up $0.02 during mid-day trading on Friday, reaching $63.07. 1,201,964 shares of the company were exchanged, compared to its average volume of 2,071,804. Catalent, Inc. has a 1 year low of $40.29 and a 1 year high of $63.25. The firm has a 50-day moving average of $60.30 and a 200 day moving average of $59.04. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of -27.91, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the company posted ($0.10) earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year. On average, research analysts expect that Catalent, Inc. will post 0.78 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on CTLT. Baird R W downgraded shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. StockNews.com lowered Catalent from a "hold" rating to a "sell" rating in a research report on Tuesday, December 10th. Robert W. Baird reissued a "neutral" rating and set a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.